Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 3

Conditions

Ovarian Neoplasms 5Neoplasms 3Glioblastoma 3Squamous Cell Carcinoma of Head and Neck 1Rare Tumour 1Neoadjuvant Therapy 1Metastatic Castration-resistant Prostate Cancer 1Locally Advanced Prostate Cancer 1Limited Stage Small Cell Lung Cancer 1Hereditary leiomyomatosis and renal cell cancer 1Head and Neck Neoplasms 1Glioma 1Carcinosarcoma 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Advanced Malignant Solid Neoplasm 1

Interventions

Surveys and Questionnaires 114Exercise 103Blood Specimen Collection 99Radiotherapy 67Gemcitabine 64Bevacizumab 57Standard of Care 56Cisplatin 55Cyclophosphamide 51Capecitabine 50Carboplatin 49Docetaxel 47pembrolizumab 46Dexamethasone 46Paclitaxel 45Interviews as Topic 43Oxaliplatin 40Magnetic Resonance Spectroscopy 39Fluorouracil 37Methods 36Irinotecan 36Therapeutics 33Drug Therapy 33Radiosurgery 31Nivolumab 30Erlotinib Hydrochloride 27Educational Status 26Everolimus 24Leucovorin 23Control Groups 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Neoplasms × pamiparib × Clear all
NCT04774406 2023-06-06

Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

University Hospital, Caen

Completed
2,336 enrolled
Tumor-Agnostic

Neoplasms

NCT04985721 2023-03-15

IMPARP-HRD

Peter MacCallum Cancer Centre, Australia

Phase 2 Unknown
60 enrolled
Tumor-Agnostic

Neoplasms

NCT04774627 2021-09-23

Pancytopenia Related to PARP Inhibitors (PancytoRIB)

University Hospital, Caen

Completed
200 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡